Akebia Therapeutics Inc
SWB:AX9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Akebia Therapeutics Inc
SWB:AX9
|
US |
|
G
|
Gap Inc
DUS:GAP
|
US |
|
G
|
Goldman Sachs BDC Inc
F:GSB
|
US |
|
Rivco Australia Ltd
ASX:RIV
|
AU |
Intrinsic Value
Is AX9 undervalued or overvalued?
See the intrinsic value estimate for
Akebia Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Akebia Therapeutics Does
Akebia Therapeutics is a drug company focused on kidney disease. It develops and sells prescription medicines for people with chronic kidney conditions, especially patients who have anemia tied to kidney failure or treatment. Its products are used through doctors and dialysis centers, so the company’s customers are the medical providers and health systems that prescribe and dispense the drugs to patients.
- Headquarters
- United States of America US
- Employees
- 194
- IPO date
- Mar 20, 2014
Revenue & Expenses Breakdown
Akebia Therapeutics Inc
Earnings Waterfall
Akebia Therapeutics Inc
The intrinsic value for
Akebia Therapeutics Inc (AX9) under the Base Case is hidden EUR.
Compared with the current market price of 1.124 EUR, the stock appears hidden.